A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily

NCT04983589 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
230
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Allergan